Back to search

Aristotle University Of Thessaloniki (AUTH)

Η συμβολή της βιοτεχνολογίας (αλληλουχία γονιδίων) στον προσδιορισμό των γονοτύπων και στην ανάδειξη μεταλλάξεων του ιού της ηπατίτιδας Β μετά από αντι-ική θεραπεία

Abstract

dc:description

The purpose of the study was to use bi-directional PCR sequencing, in order to detect resistance mutations to lamivudine and adefovir. Using PCR sequencing assay, all mutations in the region of reverse transcriptase of the A-E domains of HBV polymerase could be identified as well as mutations correlated to drug resistance and mutations not correlated to drug resistance. One hundred patients with chronic HBeAg (–) chronic hepatitis B participated in the study and were initially treated with lamivudine. At baseline and every 3 months thereafter, biochemical, aminotransferase levels and viral load were examined. The results of the present study showed that the mean time of resistance to lamivudine treatment was 34.8±17.73 months and that the elevation of viral load from nadir and ALT showed a high deviation among patients with a mean ALT level of 165.5±247.49 and mean HBV DNA 26.3±76.11 (x106 copies /ml). Concerning resistance mutations under the pressure of lamivudine, the following was observed: 3 patients had a mutation in position 180, 66 in 180+204, 30 in 204 and 1 patient in position 173+204. Furthermore, it was found that levels of HBV DNA tended to be a significant marker of resistance time prediction (<0.007), that is lower baseline levels of HBV DNA were correlated with longer time of antiviral resistance to lamivudine treatment (Beta= –0.203). Using the correlation co-efficient, ALT and AST levels were found to have a significant correlation with time of resistance (r=0.621, p<0.0001). Ninety-three/100 patients with resistance to lamivudine were then treated with adefovir as a rescue therapy, in 75 of them adefovir was added to lamivudine and in 11 adefovir was given as monotherapy. In the remaining 9 patients, adefovir and entecavir were given and in 5 more, adefovir was changed to entecavir because of partial response to adefovir. In conclusion, our results showed that genotypic analysis defines the presence of antiviral resistance to the specific drug used for the treatment of chronic hepatitis B, during the time of virologic/biochemical breakthrough, discriminating resistance to partial response to treatment or non-adherence to treatment. Furthermore, our findings support the use of a sensitive assay such as PCR sequencing in detecting both primary and compensatory emerging resistance mutations to the initial therapy so that the drugs used as a rescue therapy do not show cross-resistance or develop multidrug resistance.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koumerkeridis, Georgios
  • Κουμερκερίδης, Γεώργιος

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/19488

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koumerkeridis, Georgios; Κουμερκερίδης, Γεώργιος. Η συμβολή της βιοτεχνολογίας (αλληλουχία γονιδίων) στον προσδιορισμό των γονοτύπων και στην ανάδειξη μεταλλάξεων του ιού της ηπατίτιδας Β μετά από αντι-ική θεραπεία. Aristotle University Of Thessaloniki (AUTH), 2009. http://hdl.handle.net/10442/hedi/19488